OneSource Specialty Pharma Reports 26% Revenue Decline as Semaglutide Approval Delays Hit Q3 Performance
核心洞察
OneSource Specialty Pharma (搜索) reported a 26% year-over-year revenue decline to ₹2,903 million in Q3FY26, primarily due to delayed customer approvals for semaglutide in Canada.
The company's EBITDA plummeted 88% to ₹173 million with margins collapsing from 36% to 6%, while net profit swung to a significant loss of ₹887 million.
Despite quarterly setbacks, OneSource reaffirmed its FY28 guidance targeting $400 million in organic revenue and highlighted the growing GLP-1 (搜索) market opportunity projected to reach $170 billion by 2033.
OneSource Specialty Pharma (搜索) Limited reported a sharp 26% year-over-year revenue decline to ₹2,903 million in its third quarter of fiscal year 2026, as regulatory approval delays for semaglutide in Canada significantly impacted the company's financial performance. The pharmaceutical manufacturer's stock tumbled as much as 18% following the disappointing results.
Financial Performance Deteriorates Amid Regulatory Hurdles
The company's financial metrics reflected the severity of the regulatory setback. EBITDA collapsed 88% year-over-year to ₹173 million, with margins plummeting from 36.1% in the prior year quarter to just 6.0%. Operating expenses rose 9% year-over-year to ₹273 million, exacerbating the impact of reduced revenue. Net profit swung to a significant loss of ₹887 million, highlighting the operational challenges faced during the quarter.
The revenue decline stems from delays in customer approvals for semaglutide in Canada, where OneSource serves as the manufacturing partner for Dr. Reddy's Laboratories. Dr. Reddy's faced a setback with a Notice of Non-Compliance from Health Canada, directly impacting OneSource's transition from manufacturing services agreements to commercial supply agreements and affecting revenue recognition.
Semaglutide Market Dynamics and Regulatory Landscape
The Canadian market for semaglutide represents a critical opportunity as Novo Nordisk's patent protection expired in January 2026, opening the door for generic competition. However, the regulatory approval process has proven more challenging than anticipated, with Health Canada's scrutiny delaying market entry for several players.
CEO & MD Neeraj Sharma emphasized that underlying demand remains intact and the company's order book continues to trend upwards despite the quarterly setbacks. The delay has prolonged the transition to higher-margin commercial supply agreements, but management expressed confidence in the eventual resolution of regulatory hurdles.
Long-Term Growth Prospects and Market Opportunity
Despite the challenging quarter, OneSource reaffirmed its fiscal year 2028 guidance, targeting $400 million in organic revenue and potentially $500 million including recently proposed acquisitions. The company maintains its robust EBITDA margin target of approximately 40%, subject to shareholder approvals.
Management highlighted the significant growth potential in the GLP-1 (搜索) agonist market, which is projected to expand from $48.84 billion by 2030 to over $170 billion by 2033. This growth is driven by increasing demand for obesity (搜索) and diabetes (搜索) treatments as patent protections expire in over 130 countries, creating substantial opportunities for generic manufacturers.
Strategic Positioning and Future Outlook
OneSource has strengthened its biologics platform by onboarding another global biosimilar player, demonstrating continued interest in the company's manufacturing capabilities. The company's market capitalization as of January 27, 2026, hovered around ₹15,000-₹16,400 crore, with stock trading near ₹1,300-₹1,430.
A positive development for investor confidence was the reduction in promoter share pledging to 18.52% in the December 2025 quarter from 26.04% in the September 2025 quarter, often viewed as a sign of improved financial stability. The company anticipates recovery as customer approvals progress and expects to benefit from the anticipated global surge in GLP-1 (搜索) drug demand.